Low-level viraemia on HAART: Significance and management

Current Opinion in Infectious Diseases

Volumn 25, Issue 1, 2012, Pages 17-25

  Doyle, Tomas ^a   Geretti, Anna Maria ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

HAART; HIV 1 RNA; Reservoirs; Viral load

Indexed keywords

ABACAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PLACEBO; RALTEGRAVIR; RITONAVIR; STAVUDINE; TENOFOVIR; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADD ON THERAPY; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL PRACTICE; DNA SEQUENCE; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIMIT OF QUANTITATION; MONOTHERAPY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REAL TIME POLYMERASE CHAIN REACTION; REVIEW; RNA SEQUENCE; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 84155162676     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32834ef5d9     Document Type: Review

References (34)

1. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. J Am Med Assoc 2010; 304:321-333.
2. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Sciences, (2011). http://www.aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf. [Accessed 6 December 2011]
3. European AIDS Clinical Society. European Guidelines for treatment of HIV infected adults in Europe. Version 6, (2011). http://www.europeanaidsclini calsociety.org/images/stories/EACS-Pdf/eacsguidelines-v6-english.pdf. [Accessed 6 December 2011]
4. Karasi JC, Dziezuk F, Quennery L, et al. High correlation between the Roche COBAS(1) AmpliPrep/COBAS(1) TaqMan(1) HIV-1, v2.0 and the Abbott m2000 RealTime HIV-1 assays for quantification of viral load in HIV-1 B and non-B subtypes. Clin Virol 2011; 52:181-186.
5. Glaubitz J, Sizmann D, Simon CO, et al. Accuracy to 2nd International HIV-1 RNA WHO Standard: assessment of three generations of quantitative HIV-1 RNA nucleic acid amplification tests. J Clin Virol 2011; 50:119-124.
6. van Rensburg EJ, Tait K, Watt A, et al. Comparative evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 version 2 test using the TaqMan 48 analyzer and the Abbott RealTime HIV-1 assay. J Clin Microbiol 2011; 49:377-379.
7. Sire JM, Vray M, Merzouk M, et al. Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assays. J Acquir Immune Defic Syndr 2011; 56:239-243.
8. Palmer S, Maldarelli F, Wiegand A, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A 2008; 10:3879-3884.
9. Yukl SA, Li P, Fujimoto K, Lampiris H, et al. Modification of the Abbott Real Time assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter. J Virol Methods 2011; 175:261-265.
10. Amendola A, Bloisi M, Marsella P, et al. Standardization and performance evaluation of 'modified' and 'ultrasensitive' versions of the Abbott RealTime HIV-1 assay, adapted to quantify minimal residual viremia. J Clin Virol 2011; 52:17-22.
11. Lohse N, Kronborg G, Gerstoft J, et al. Virological control during the first 6-18 months after initiating highly active antiretroviral therapy as a predictor for outcome in HIV-infected patients: a Danish, population-based, 6-year followup study. Clin Infect Dis 2006; 42:136-144.
12. Geretti AM, Smith C, Haberl A, et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther 2008; 13:927-936.
13. Doyle T, Smith C, Vitiello P, et al. Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy (HAART). Clin Infect Dis (in press).
14. Dinoso JB, Kim SY, Wiegand AM, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A 2009; 106:9403-9408.
15. Bailey JR, Sedaghat AR, Kieffer T, et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol 2006; 80:6441-6447.
16. Anderson JA, Archin NM, Ince W, et al. Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells. J Virol 2011; 85:5220-5223.
17. Shiu C, Cunningham CK, Greenough T, et al. Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy. J Virol 2009; 83:9731-9742.
18. Sigal A, Kim JT, Balazs AB, et al. Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature 2011; 477:95-98.
19. Sahu GK, Sarria JC, Cloyd MW. Recovery of replication-competent residual HIV-1 from plasma of a patient receiving prolonged, suppressive highly active antiretroviral therapy. J Virol 2010; 84:8348-8352.
20. Chun TW, Murray D, Justement JS, et al. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy. J Infect Dis 2011; 204:135-138.
21. Yukl SA, Gianella S, Sinclair E, et al. Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis 2010; 202:1553-1561.
22. Lafeuillade A, Cheret A, Hittinger G, et al. Rectal cell-associated HIV-1 RNA: a new marker ready for the clinic. HIV Clin Trials 2009; 10:324-327.
23. North TW, Higgins J, Deere JD, et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol 2010; 84:2913-2922.
24. Lerner P, Guadalupe M, Donovan R, et al. The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy. J Virol 2011; 85:4772-4782.
25. Bonora S, Nicastri E, Calcagno A, et al. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. J Med Virol 2009; 81:400-405.
26. Haïm-Boukobza S, Morand-Joubert L, Flandre P, et al. Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml. AIDS 2011; 25:341-344.
27. Havlir DV, Strain MC, Clerici M, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1- infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77:11212-11219.
28. Lindkvist A, Edén A, Norström MM, et al. Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study. AIDS Res Ther 2009;6:15.
29. Mellberg T, Gonzalez VD, Lindkvist A, et al. Rebound of residual plasma viremia after initial decrease following addition of intravenous immunoglobulin to effective antiretroviral treatment of HIV. AIDS Res Ther 2011; 8:21.
30. Wilkin TJ, McKinnon JE, DiRienzo AG, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis 2009; 199:866-871.
31. McMahon D, Jones J, Wiegand A, et al. Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis 2010;50:912-919.
32. Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med 2010; 7:e1000321.
33. Hatano H, Hayes TL, Dahl V, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis 2011; 203:960-968.
34. Yukl SA, Shergill AK, McQuaid K, et al. Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy. AIDS 2010;24:2451-2460.